The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

NCT00856609 on ClinicalTrials.gov · last registry update 2019-06-04

A small phase 3 — 150 participants, against a typical 424. The sponsor logged completion for 19 September 2016. Primary outcome, as filed: Energy Intake. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor type: Nih
Enrollment: 150
Started: 2009-03-03
Primary completion: 2016-09-19 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Energy Intake

Conditions studied

Weight Loss · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.